{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:19:12Z","timestamp":1787786352779,"version":"build-2784847793"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T00:00:00Z","timestamp":1658534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T00:00:00Z","timestamp":1658534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Low molecular weight heparins (LMWHs) are a group of heterogenous moieties, long used in the prevention and treatment of thrombosis. They derive from heparin and since they are prepared by different methods of depolymerization, they differ in pharmacokinetic properties and anticoagulant profiles, and thus are not clinically interchangeable.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this review we provide an overview of tinzaparin's main characteristics and uses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Tinzaparin which is produced by the enzymatic depolymerization of unfractionated heparin (UFH) can be used for the treatment and prevention of deep venous thrombosis (DVT) and pulmonary embolism (PE); it has been also used in special populations such as elders, obese, pregnant women, and patients with renal impairment and\/or cancer with favorable outcomes in both safety and efficacy, with a once daily dose regimen. Furthermore, LMWHs are extensively used in clinical practice for both thromboprophylaxis and thrombosis treatment of COVID-19 patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Tinzaparin features support the hypothesis for having a role in\u00a0immunothrombosis treatment\u00a0(i.e. in the context of cancer ,COVID-19), interfering not only with coagulation cascade but also exhibiting anti-inflammatory potency.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00228-022-03365-4","type":"journal-article","created":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T18:13:32Z","timestamp":1658600012000},"page":"1555-1565","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Tinzaparin\u2014a review of its molecular profile, pharmacology, special properties, and clinical uses"],"prefix":"10.1007","volume":"78","author":[{"given":"Marina","family":"Amerali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Politou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,23]]},"reference":[{"issue":"5","key":"3365_CR1","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1097\/00001573-199409000-00017","volume":"9","author":"B Cosmi","year":"1994","unstructured":"Cosmi B, Hirsh J (1994) Low molecular weight heparins. Curr Opin Cardiol 9(5):612\u2013618. https:\/\/doi.org\/10.1097\/00001573-199409000-00017","journal-title":"Curr Opin Cardiol"},{"key":"3365_CR2","doi-asserted-by":"publisher","unstructured":"Akhtar F, Wan X, Wu G, Kesse S, Wang S, He S (2018) Low-molecular-weight heparins: reduced size particulate systems for improved therapeutic outcomes. Molecules (Basel, Switzerland) 23(7). https:\/\/doi.org\/10.3390\/molecules23071757","DOI":"10.3390\/molecules23071757"},{"issue":"4","key":"3365_CR3","doi-asserted-by":"publisher","first-page":"326","DOI":"10.3109\/10409238.2015.1050550","volume":"50","author":"SA Smith","year":"2015","unstructured":"Smith SA, Travers RJ, Morrissey JH (2015) How it all starts: initiation of the clotting cascade. Crit Rev Biochem Mol Biol 50(4):326\u2013336. https:\/\/doi.org\/10.3109\/10409238.2015.1050550","journal-title":"Crit Rev Biochem Mol Biol"},{"issue":"3","key":"3365_CR4","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1080\/09537104.2020.1817360","volume":"32","author":"K Martinod","year":"2021","unstructured":"Martinod K, Deppermann C (2021) Immunothrombosis and thromboinflammation in host defense and disease. Platelets 32(3):314\u2013324. https:\/\/doi.org\/10.1080\/09537104.2020.1817360","journal-title":"Platelets"},{"key":"3365_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/bs.pmbts.2019.02.003","volume":"163","author":"C Hao","year":"2019","unstructured":"Hao C, Sun M, Wang H, Zhang L, Wang W (2019) Low molecular weight heparins and their clinical applications. Prog Mol Biol Transl Sci 163:21\u201339. https:\/\/doi.org\/10.1016\/bs.pmbts.2019.02.003","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"Suppl 1","key":"3365_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1055\/s-2000-9497","volume":"26","author":"MM Samama","year":"2000","unstructured":"Samama MM, Gerotziafas GT (2000) Comparative pharmacokinetics of LMWHs. Semin Thromb Hemost 26(Suppl 1):31\u201338. https:\/\/doi.org\/10.1055\/s-2000-9497","journal-title":"Semin Thromb Hemost"},{"issue":"1","key":"3365_CR7","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1046\/j.1365-2141.2002.03233.x","volume":"116","author":"MA Crowther","year":"2002","unstructured":"Crowther MA, Berry LR, Monagle PT, Chan AK (2002) Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin. Br J Haematol 116(1):178\u2013186. https:\/\/doi.org\/10.1046\/j.1365-2141.2002.03233.x","journal-title":"Br J Haematol"},{"key":"3365_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-022-03318-x","author":"J Bouget","year":"2022","unstructured":"Bouget J, Balusson F, Kerbrat S, Roy PM, Viglino D, Lacut K et al (2022) Clinical use of low-dose parenteral anticoagulation, incidence of major bleeding and mortality: a multi-centre cohort study using the French national health data system. Eur J Clin Pharmacol. https:\/\/doi.org\/10.1007\/s00228-022-03318-x","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"3365_CR9","doi-asserted-by":"publisher","first-page":"305","DOI":"10.21873\/anticanres.13954","volume":"40","author":"P Papakotoulas","year":"2020","unstructured":"Papakotoulas P, Tsoukalas N, Christopoulou A, Ardavanis A, Koumakis G, Papandreou C et al (2020) Management of cancer-associated thrombosis (CAT): symptomatic or incidental. Anticancer Res 40(1):305\u2013313. https:\/\/doi.org\/10.21873\/anticanres.13954","journal-title":"Anticancer Res"},{"key":"3365_CR10","doi-asserted-by":"publisher","unstructured":"Tsoukalas N, Papakotoulas P, Christopoulou A, Ardavanis A, Koumakis G, Papandreou C et al (2020) Real-world data on thromboprophylaxis in active cancer patients: where are we? Are we getting there? Cancers (Basel) 12(7). https:\/\/doi.org\/10.3390\/cancers12071907","DOI":"10.3390\/cancers12071907"},{"issue":"2","key":"3365_CR11","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s00216-010-4220-8","volume":"399","author":"M Schroeder","year":"2011","unstructured":"Schroeder M, Hogwood J, Gray E, Mulloy B, Hackett A-M, Johansen KB (2011) Protamine neutralisation of low molecular weight heparins and their oligosaccharide components. Anal Bioanal Chem 399(2):763\u2013771. https:\/\/doi.org\/10.1007\/s00216-010-4220-8","journal-title":"Anal Bioanal Chem"},{"issue":"1","key":"3365_CR12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/2162-3619-2-21","volume":"2","author":"KB Johansen","year":"2013","unstructured":"Johansen KB, Balchen T (2013) Tinzaparin and other low-molecular-weight heparins: what is the evidence for differential dependence on renal clearance? Exp Hematol Oncol 2(1):21. https:\/\/doi.org\/10.1186\/2162-3619-2-21","journal-title":"Exp Hematol Oncol"},{"key":"3365_CR13","unstructured":"Council of Europe (2004a)\u00a0Tinzaparin sodium, monograph 1271. European Pharmacopoeia. 5th ed. Strasbourg: p. 2586"},{"key":"3365_CR14","unstructured":"Council of Europe (2004b)\u00a0Dalteparin sodium, monograph 1195. European Pharmacopoeia. 5th Suppl. 5.4 ed. Strasbourg: p. 3925\u20136"},{"key":"3365_CR15","unstructured":"Council of Europe (2004c)\u00a0Enoxaparin sodium, monograph 1097. European Pharmacopoeia. 5th Suppl. 5.3 ed. Strasbourg: p. 3493\u20134"},{"key":"3365_CR16","unstructured":"Council of Europe (2004d)\u00a0Nadroparin calcium, monograph 1134. European Pharmacopoeia. 5th ed. Strasbourg: p. 2075\u20137"},{"issue":"Suppl 3","key":"3365_CR17","first-page":"63","volume":"25","author":"HB Nader","year":"1999","unstructured":"Nader HB, Walenga JM, Berkowitz SD, Ofosu F, Hoppensteadt DA, Cella G (1999) Preclinical differentiation of low molecular weight heparins. Semin Thromb Hemost 25(Suppl 3):63\u201372","journal-title":"Semin Thromb Hemost"},{"issue":"Suppl 3","key":"3365_CR18","first-page":"5","volume":"25","author":"RJ Linhardt","year":"1999","unstructured":"Linhardt RJ, Gunay NS (1999) Production and chemical processing of low molecular weight heparins. Semin Thromb Hemost 25(Suppl 3):5\u201316","journal-title":"Semin Thromb Hemost"},{"issue":"5","key":"3365_CR19","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1111\/j.1538-7836.2007.02477.x","volume":"5","author":"GT Gerotziafas","year":"2007","unstructured":"Gerotziafas GT, Petropoulou AD, Verdy E, Samama MM, Elalamy I (2007) Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation. J Thromb Haemost 5(5):955\u2013962. https:\/\/doi.org\/10.1111\/j.1538-7836.2007.02477.x","journal-title":"J Thromb Haemost"},{"key":"3365_CR20","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1385\/1-59259-658-4:49","volume":"93","author":"SA Mousa","year":"2004","unstructured":"Mousa SA (2004) Are low molecular weight heparins the same? Methods Mol Med 93:49\u201359. https:\/\/doi.org\/10.1385\/1-59259-658-4:49","journal-title":"Methods Mol Med"},{"issue":"4","key":"3365_CR21","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/s0049-3848(00)00412-6","volume":"101","author":"JS Barrett","year":"2001","unstructured":"Barrett JS, Hainer JW, Kornhauser DM, Gaskill JL, Hua TA, Sprogel P et al (2001) Anticoagulant pharmacodynamics of tinzaparin following 175 iu\/kg subcutaneous administration to healthy volunteers. Thromb Res 101(4):243\u2013254. https:\/\/doi.org\/10.1016\/s0049-3848(00)00412-6","journal-title":"Thromb Res"},{"issue":"5","key":"3365_CR22","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1160\/TH09-02-0081","volume":"102","author":"A Bisio","year":"2009","unstructured":"Bisio A, Vecchietti D, Citterio L, Guerrini M, Raman R, Bertini S et al (2009) Structural features of low-molecular-weight heparins affecting their affinity to antithrombin. Thromb Haemost 102(5):865\u2013873. https:\/\/doi.org\/10.1160\/TH09-02-0081","journal-title":"Thromb Haemost"},{"issue":"5","key":"3365_CR23","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/j.1365-2044.2004.03679.x","volume":"59","author":"GC Price","year":"2004","unstructured":"Price GC, Thompson SA, Kam PC (2004) Tissue factor and tissue factor pathway inhibitor. Anaesthesia 59(5):483\u2013492. https:\/\/doi.org\/10.1111\/j.1365-2044.2004.03679.x","journal-title":"Anaesthesia"},{"issue":"10","key":"3365_CR24","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1056\/NEJM199709043371007","volume":"337","author":"JI Weitz","year":"1997","unstructured":"Weitz JI (1997) Low-molecular-weight heparins. N Engl J Med 337(10):688\u2013698. https:\/\/doi.org\/10.1056\/NEJM199709043371007","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"3365_CR25","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1159\/000054163","volume":"30","author":"PM Sandset","year":"2000","unstructured":"Sandset PM, Bendz B, Hansen JB (2000) Physiological function of tissue factor pathway inhibitor and interaction with heparins. Haemostasis 30(Suppl 2):48\u201356. https:\/\/doi.org\/10.1159\/000054163","journal-title":"Haemostasis"},{"issue":"4","key":"3365_CR26","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1046\/j.1365-2141.1999.01791.x","volume":"107","author":"B Bendz","year":"1999","unstructured":"Bendz B, Hansen JB, Andersen TO, Ostergaard P, Sandset PM (1999) Partial depletion of tissue factor pathway inhibitor during subcutaneous administration of unfractionated heparin, but not with two low molecular weight heparins. Br J Haematol 107(4):756\u2013762. https:\/\/doi.org\/10.1046\/j.1365-2141.1999.01791.x","journal-title":"Br J Haematol"},{"issue":"12","key":"3365_CR27","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1111\/j.1538-7836.2003.0543k.x","volume":"1","author":"I Gouin-Thibault","year":"2003","unstructured":"Gouin-Thibault I, Pautas E, Depasse F, Andreux JP, Siguret V (2003) Heparin-releasable TFPI is not depleted after repeated injections of tinzaparin at therapeutic dose for up to 30 days. J Thromb Haemost 1(12):2694\u20132695. https:\/\/doi.org\/10.1111\/j.1538-7836.2003.0543k.x","journal-title":"J Thromb Haemost"},{"issue":"Suppl 1","key":"3365_CR28","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1055\/s-2004-823003","volume":"30","author":"DA Hoppensteadt","year":"2004","unstructured":"Hoppensteadt DA, Willows L, Leitz H, Nicolaides A, Fareed J (2004) Laboratory analysis of blood samples from patients treated with tinzaparin. Semin Thromb Hemost 30(Suppl 1):49\u201355. https:\/\/doi.org\/10.1055\/s-2004-823003","journal-title":"Semin Thromb Hemost"},{"key":"3365_CR29","doi-asserted-by":"publisher","unstructured":"Depasse F, Gonzalez de Suso MJ, Lagoutte I, Fontcuberta J, Borrell M, Samama MM (2003) Comparative study of the pharmacokinetic profiles of two LMWHs--bemiparin (3500 IU, anti-Xa) and tinzaparin (4500 IU, anti-Xa)--administered subcutaneously to healthy male volunteers. Thrombosis Res 109(2\u20133):109\u201317. https:\/\/doi.org\/10.1016\/s0049-3848(03)00141-5","DOI":"10.1016\/s0049-3848(03)00141-5"},{"issue":"6","key":"3365_CR30","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/0049-3848(86)90100-3","volume":"43","author":"C Caranobe","year":"1986","unstructured":"Caranobe C, Petitou M, Dupouy D, Gabaig AM, Sie P, Buchanan MR et al (1986) Heparin fractions with high and low affinities to antithrombin III are cleared at different rates. Thromb Res 43(6):635\u2013641. https:\/\/doi.org\/10.1016\/0049-3848(86)90100-3","journal-title":"Thromb Res"},{"key":"3365_CR31","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/2162-3619-2-21","volume":"2","author":"KB Johansen","year":"2013","unstructured":"Johansen KB, Balchen T (2013) Tinzaparin and other low-molecular-weight heparins: what is the evidence for differential dependence on renal clearance? Exp Hematol Oncol 2:21. https:\/\/doi.org\/10.1186\/2162-3619-2-21","journal-title":"Exp Hematol Oncol"},{"issue":"3","key":"3365_CR32","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s40256-019-00382-0","volume":"20","author":"H Helfer","year":"2020","unstructured":"Helfer H, Siguret V, Mahe I (2020) Tinzaparin sodium pharmacokinetics in patients with chronic kidney disease: practical implications. American journal of cardiovascular drugs\u202f: drugs, devices, and other interventions 20(3):223\u2013228. https:\/\/doi.org\/10.1007\/s40256-019-00382-0","journal-title":"American journal of cardiovascular drugs : drugs, devices, and other interventions"},{"issue":"10","key":"3365_CR33","first-page":"431","volume":"39","author":"JS Barrett","year":"2001","unstructured":"Barrett JS, Gibiansky E, Hull RD, Planes A, Pentikis H, Hainer JW et al (2001) Population pharmacodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis. Int J Clin Pharmacol Ther 39(10):431\u2013446","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"17","key":"3365_CR34","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1093\/ajhp\/58.17.1614","volume":"58","author":"MJ Fossler","year":"2001","unstructured":"Fossler MJ, Barrett JS, Hainer JW, Riddle JG, Ostergaard P, van der Elst E et al (2001) Pharmacodynamics of intravenous and subcutaneous tinzaparin and heparin in healthy volunteers. Am J Health-syst Pharma\u202f: AJHP\u202f: Official J Am S Health-Syst Pharma 58(17):1614\u20131621. https:\/\/doi.org\/10.1093\/ajhp\/58.17.1614","journal-title":"Am J Health-syst Pharma : AJHP : Official J Am S Health-Syst Pharma"},{"issue":"20","key":"3365_CR35","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1056\/NEJM199505183322003","volume":"332","author":"TE Warkentin","year":"1995","unstructured":"Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M et al (1995) Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 332(20):1330\u20131335. https:\/\/doi.org\/10.1056\/NEJM199505183322003","journal-title":"N Engl J Med"},{"key":"3365_CR36","doi-asserted-by":"publisher","unstructured":"Bhutia S, Wong PF (2013) Once versus twice daily low molecular weight heparin for the initial treatment of venous thromboembolism. Cochrane Database System Rev (7):CD003074. https:\/\/doi.org\/10.1002\/14651858.CD003074.pub3","DOI":"10.1002\/14651858.CD003074.pub3"},{"issue":"3","key":"3365_CR37","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1177\/1060028017737094","volume":"52","author":"K Fuller","year":"2018","unstructured":"Fuller K, Malecki S, Anselmo L, Borrego ME, Jakeman B, Burnett A (2018) Once-daily versus twice-daily enoxaparin for the treatment of acute venous thromboembolism in cancer patients. Ann Pharmacother 52(3):257\u2013262. https:\/\/doi.org\/10.1177\/1060028017737094","journal-title":"Ann Pharmacother"},{"key":"3365_CR38","doi-asserted-by":"publisher","unstructured":"Niu J, Song Y, Li C, Ren H, Zhang W (2020) Once-daily vs. twice-daily dosing of enoxaparin for the management of venous thromboembolism: a systematic review and meta-analysis. Exp Ther Med 20(4):3084\u201395. https:\/\/doi.org\/10.3892\/etm.2020.9036","DOI":"10.3892\/etm.2020.9036"},{"issue":"3","key":"3365_CR39","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/jth.13616","volume":"15","author":"J Trujillo-Santos","year":"2017","unstructured":"Trujillo-Santos J, Bergmann JF, Bortoluzzi C, Lopez-Reyes R, Giorgi-Pierfranceschi M, Lopez-Saez JB et al (2017) Once versus twice daily enoxaparin for the initial treatment of acute venous thromboembolism. J Thromb Haemost 15(3):429\u2013438. https:\/\/doi.org\/10.1111\/jth.13616","journal-title":"J Thromb Haemost"},{"key":"3365_CR40","doi-asserted-by":"publisher","unstructured":"Siegbahn A, S YH, Boberg J, Bylund H, Neerstrand HS, Ostergaard P et al (1989) Subcutaneous treatment of deep venous thrombosis with low molecular weight heparin. A dose finding study with LMWH-Novo. Thromb Res 55(6):767\u201378. https:\/\/doi.org\/10.1016\/0049-3848(89)90307-1","DOI":"10.1016\/0049-3848(89)90307-1"},{"issue":"2","key":"3365_CR41","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.ejogrb.2011.08.005","volume":"159","author":"C Nelson-Piercy","year":"2011","unstructured":"Nelson-Piercy C, Powrie R, Borg JY, Rodger M, Talbot DJ, Stinson J et al (2011) Tinzaparin use in pregnancy: an international, retrospective study of the safety and efficacy profile. Eur J Obstet Gynecol Reprod Biol 159(2):293\u2013299. https:\/\/doi.org\/10.1016\/j.ejogrb.2011.08.005","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"1","key":"3365_CR42","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/j.1479-828X.2011.01361.x","volume":"52","author":"C McLintock","year":"2012","unstructured":"McLintock C, Brighton T, Chunilal S, Dekker G, McDonnell N, McRae S et al (2012) Recommendations for the diagnosis and treatment of deep venous thrombosis and pulmonary embolism in pregnancy and the postpartum period. Aust N Z J Obstet Gynaecol 52(1):14\u201322. https:\/\/doi.org\/10.1111\/j.1479-828X.2011.01361.x","journal-title":"Aust N Z J Obstet Gynaecol"},{"issue":"2","key":"3365_CR43","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.thromres.2012.11.022","volume":"131","author":"C Nelson-Piercy","year":"2013","unstructured":"Nelson-Piercy C, Greer IA (2013) Anticoagulation with tinzaparin for women with mechanical valves in pregnancy: a retrospective case series. Thromb Res 131(2):185\u2013186. https:\/\/doi.org\/10.1016\/j.thromres.2012.11.022","journal-title":"Thromb Res"},{"issue":"2","key":"3365_CR44","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s11845-013-0998-7","volume":"183","author":"A Khalifeh","year":"2014","unstructured":"Khalifeh A, Grantham J, Byrne J, Murphy K, McAuliffe F, Byrne B (2014) Tinzaparin safety and efficacy in pregnancy. Ir J Med Sci 183(2):249\u2013252. https:\/\/doi.org\/10.1007\/s11845-013-0998-7","journal-title":"Ir J Med Sci"},{"issue":"2","key":"3365_CR45","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/s0002-9378(03)00953-0","volume":"190","author":"MP Smith","year":"2004","unstructured":"Smith MP, Norris LA, Steer PJ, Savidge GF, Bonnar J (2004) Tinzaparin sodium for thrombosis treatment and prevention during pregnancy. Am J Obstet Gynecol 190(2):495\u2013501. https:\/\/doi.org\/10.1016\/s0002-9378(03)00953-0","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"3365_CR46","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1097\/01.mcp.0000136405.17204.5e","volume":"10","author":"MD McColl","year":"2004","unstructured":"McColl MD, Greer IA (2004) Low-molecular-weight heparin for the prevention and treatment of venous thromboembolism in pregnancy. Curr Opin Pulm Med 10(5):371\u2013375. https:\/\/doi.org\/10.1097\/01.mcp.0000136405.17204.5e","journal-title":"Curr Opin Pulm Med"},{"issue":"5","key":"3365_CR47","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1055\/s-0037-1613090","volume":"87","author":"JW Hainer","year":"2002","unstructured":"Hainer JW, Barrett JS, Assaid CA, Fossler MJ, Cox DS, Leathers T et al (2002) Dosing in heavy-weight\/obese patients with the LMWH, tinzaparin: a pharmacodynamic study. Thromb Haemost 87(5):817\u2013823","journal-title":"Thromb Haemost"},{"issue":"3","key":"3365_CR48","first-page":"278","volume":"24","author":"SA Mousa","year":"2005","unstructured":"Mousa SA (2005) Elevation of plasma von Willebrand factor and tumor necrosis factor-a in obese subjects and their reduction by the low molecular weight heparin tinzaparin. Int Angiol\u202f: J Int Union Angiol 24(3):278\u2013281","journal-title":"Int Angiol : J Int Union Angiol"},{"issue":"31\u201332","key":"3365_CR49","doi-asserted-by":"publisher","first-page":"438","DOI":"10.4414\/smw.2009.11284","volume":"139","author":"P Schmid","year":"2009","unstructured":"Schmid P, Fischer AG, Wuillemin WA (2009) Low-molecular-weight heparin in patients with renal insufficiency. Swiss Med Wkly 139(31\u201332):438\u2013452. https:\/\/doi.org\/10.4414\/smw.2009.11284","journal-title":"Swiss Med Wkly"},{"issue":"3","key":"3365_CR50","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1053\/ajkd.2002.34911","volume":"40","author":"JW Hainer","year":"2002","unstructured":"Hainer JW, Sherrard DJ, Swan SK, Barrett JS, Assaid CA, Fossler MJ et al (2002) Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis. Am J Kidney Dis 40(3):531\u2013538. https:\/\/doi.org\/10.1053\/ajkd.2002.34911","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"3365_CR51","first-page":"800","volume":"84","author":"V Siguret","year":"2000","unstructured":"Siguret V, Pautas E, Fevrier M, Wipff C, Durand-Gasselin B, Laurent M et al (2000) Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU\/kg): anti-Xa and anti-IIa activities over 10 days. Thromb Haemost 84(5):800\u2013804","journal-title":"Thromb Haemost"},{"issue":"10","key":"3365_CR52","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1111\/j.1538-7836.2011.04458.x","volume":"9","author":"V Siguret","year":"2011","unstructured":"Siguret V, Gouin-Thibault I, Pautas E, Leizorovicz A (2011) No accumulation of the peak anti-factor Xa activity of tinzaparin in elderly patients with moderate-to-severe renal impairment: the IRIS substudy. J Thromb Haemost 9(10):1966\u20131972. https:\/\/doi.org\/10.1111\/j.1538-7836.2011.04458.x","journal-title":"J Thromb Haemost"},{"issue":"22","key":"3365_CR53","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1001\/archinte.162.22.2605","volume":"162","author":"J Nagge","year":"2002","unstructured":"Nagge J, Crowther M, Hirsh J (2002) Is impaired renal function a contraindication to the use of low-molecular-weight heparin? Arch Intern Med 162(22):2605\u20132609. https:\/\/doi.org\/10.1001\/archinte.162.22.2605","journal-title":"Arch Intern Med"},{"issue":"2","key":"3365_CR54","first-page":"237","volume":"2","author":"E Tincani","year":"2007","unstructured":"Tincani E, Crowther MA, Turrini F, Prisco D (2007) Prevention and treatment of venous thromboembolism in the elderly patient. Clin Interv Aging 2(2):237\u2013246","journal-title":"Clin Interv Aging"},{"issue":"10","key":"3365_CR55","doi-asserted-by":"publisher","first-page":"725","DOI":"10.2165\/00002018-200225100-00005","volume":"25","author":"E Pautas","year":"2002","unstructured":"Pautas E, Gouin I, Bellot O, Andreux JP, Siguret V (2002) Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients. Drug Saf 25(10):725\u2013733. https:\/\/doi.org\/10.2165\/00002018-200225100-00005","journal-title":"Drug Saf"},{"issue":"4","key":"3365_CR56","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1160\/TH06-09-0513","volume":"97","author":"I Mah\u00e9","year":"2007","unstructured":"Mah\u00e9 I, Aghassarian M, Drouet L, Bal Dit-Sollier C, Lacut K, Heilmann JJ et al (2007) Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study. Thromb Haemost 97(4):581\u2013586","journal-title":"Thromb Haemost"},{"issue":"5","key":"3365_CR57","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s00228-011-1149-6","volume":"68","author":"P Hoffmann","year":"2012","unstructured":"Hoffmann P, Keller F (2012) Increased major bleeding risk in patients with kidney dysfunction receiving enoxaparin: a meta-analysis. Eur J Clin Pharmacol 68(5):757\u2013765. https:\/\/doi.org\/10.1007\/s00228-011-1149-6","journal-title":"Eur J Clin Pharmacol"},{"issue":"20","key":"3365_CR58","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1001\/archinte.164.20.2260","volume":"164","author":"PD Stein","year":"2004","unstructured":"Stein PD, Hull RD, Kayali F, Ghali WA, Alshab AK, Olson RE (2004) Venous thromboembolism according to age: the impact of an aging population. Arch Intern Med 164(20):2260\u20132265. https:\/\/doi.org\/10.1001\/archinte.164.20.2260","journal-title":"Arch Intern Med"},{"key":"3365_CR59","doi-asserted-by":"publisher","unstructured":"Roopkumar J, Kim AS, Bicky T, Hobbs BP, Khorana AA (2018) Venous thromboembolism in cancer patients receiving immunotherapy. Blood 132(Supplement 1):2510-. https:\/\/doi.org\/10.1182\/blood-2018-99-116439","DOI":"10.1182\/blood-2018-99-116439"},{"issue":"7","key":"3365_CR60","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1055\/s-0029-1242718","volume":"35","author":"M Franchini","year":"2009","unstructured":"Franchini M, Montagnana M, Favaloro EJ, Lippi G (2009) The bidirectional relationship of cancer and hemostasis and the potential role of anticoagulant therapy in moderating thrombosis and cancer spread. Semin Thromb Hemost 35(7):644\u2013653. https:\/\/doi.org\/10.1055\/s-0029-1242718","journal-title":"Semin Thromb Hemost"},{"issue":"1","key":"3365_CR61","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1055\/s-2006-933341","volume":"32","author":"J Rak","year":"2006","unstructured":"Rak J, Milsom C, May L, Klement P, Yu J (2006) Tissue factor in cancer and angiogenesis: the molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy. Semin Thromb Hemost 32(1):54\u201370. https:\/\/doi.org\/10.1055\/s-2006-933341","journal-title":"Semin Thromb Hemost"},{"issue":"3","key":"3365_CR62","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1172\/JCI117451","volume":"94","author":"Y Zhang","year":"1994","unstructured":"Zhang Y, Deng Y, Luther T, Muller M, Ziegler R, Waldherr R et al (1994) Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Investig 94(3):1320\u20131327. https:\/\/doi.org\/10.1172\/JCI117451","journal-title":"J Clin Investig"},{"issue":"3 Suppl","key":"3365_CR63","doi-asserted-by":"publisher","first-page":"58S","DOI":"10.1378\/chest.124.3_suppl.58s","volume":"124","author":"FR Rickles","year":"2003","unstructured":"Rickles FR, Patierno S, Fernandez PM (2003) Tissue factor, thrombin, and cancer. Chest 124(3 Suppl):58S-68S. https:\/\/doi.org\/10.1378\/chest.124.3_suppl.58s","journal-title":"Chest"},{"issue":"5","key":"3365_CR64","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1097\/00062752-199603050-00008","volume":"3","author":"W Ruf","year":"1996","unstructured":"Ruf W, Mueller BM (1996) Tissue factor in cancer angiogenesis and metastasis. Curr Opin Hematol 3(5):379\u2013384. https:\/\/doi.org\/10.1097\/00062752-199603050-00008","journal-title":"Curr Opin Hematol"},{"issue":"1","key":"3365_CR65","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11239-007-0028-6","volume":"24","author":"M Franchini","year":"2007","unstructured":"Franchini M, Montagnana M, Targher G, Manzato F, Lippi G (2007) Pathogenesis, clinical and laboratory aspects of thrombosis in cancer. J Thromb Thrombolysis 24(1):29\u201338. https:\/\/doi.org\/10.1007\/s11239-007-0028-6","journal-title":"J Thromb Thrombolysis"},{"issue":"11","key":"3365_CR66","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1161\/ATVBAHA.108.175083","volume":"28","author":"J Yu","year":"2008","unstructured":"Yu J, May L, Milsom C, Anderson GM, Weitz JI, Luyendyk JP et al (2008) Contribution of host-derived tissue factor to tumor neovascularization. Arterioscler Thromb Vasc Biol 28(11):1975\u20131981. https:\/\/doi.org\/10.1161\/ATVBAHA.108.175083","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"3365_CR67","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1097\/00001721-200209000-00005","volume":"13","author":"A Amirkhosravi","year":"2002","unstructured":"Amirkhosravi A, Amaya M, Desai H, Francis JL (2002) Platelet-CD40 ligand interaction with melanoma cell and monocyte CD40 enhances cellular procoagulant activity. Blood Coagulat Fibrinol\u202f: Int J Haemost Thromb 13(6):505\u2013512. https:\/\/doi.org\/10.1097\/00001721-200209000-00005","journal-title":"Blood Coagulat Fibrinol : Int J Haemost Thromb"},{"issue":"2","key":"3365_CR68","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1055\/s-2008-1079254","volume":"34","author":"F Schaffner","year":"2008","unstructured":"Schaffner F, Ruf W (2008) Tissue factor and protease-activated receptor signaling in cancer. Semin Thromb Hemost 34(2):147\u2013153. https:\/\/doi.org\/10.1055\/s-2008-1079254","journal-title":"Semin Thromb Hemost"},{"issue":"Suppl 1","key":"3365_CR69","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1055\/s-2006-939555","volume":"32","author":"W Ruf","year":"2006","unstructured":"Ruf W, Mueller BM (2006) Thrombin generation and the pathogenesis of cancer. Semin Thromb Hemost 32(Suppl 1):61\u201368. https:\/\/doi.org\/10.1055\/s-2006-939555","journal-title":"Semin Thromb Hemost"},{"issue":"8","key":"3365_CR70","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1055\/s-0029-1145255","volume":"34","author":"KM Snyder","year":"2008","unstructured":"Snyder KM, Kessler CM (2008) The pivotal role of thrombin in cancer biology and tumorigenesis. Semin Thromb Hemost 34(8):734\u2013741. https:\/\/doi.org\/10.1055\/s-0029-1145255","journal-title":"Semin Thromb Hemost"},{"issue":"7","key":"3365_CR71","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1055\/s-2007-991536","volume":"33","author":"A Falanga","year":"2007","unstructured":"Falanga A, Marchetti M (2007) Heparin in tumor progression and metastatic dissemination. Semin Thromb Hemost 33(7):688\u2013694. https:\/\/doi.org\/10.1055\/s-2007-991536","journal-title":"Semin Thromb Hemost"},{"key":"3365_CR72","doi-asserted-by":"publisher","unstructured":"Mandala M, Falanga A, Roila F, Group EGW (2011) Management of venous thromboembolism (VTE) in cancer patients: ESMO clinical practice guidelines. Annals of oncology : official journal of the Euro Soc Med Oncol \/ ESMO 22 Suppl 6:vi85\u201392.\u00a0https:\/\/doi.org\/10.1093\/annonc\/mdr392","DOI":"10.1093\/annonc\/mdr392"},{"issue":"Suppl 2","key":"3365_CR73","doi-asserted-by":"publisher","first-page":"S122","DOI":"10.1016\/S0049-3848(14)50021-7","volume":"133","author":"NM Kuderer","year":"2014","unstructured":"Kuderer NM, Lyman GH (2014) Guidelines for treatment and prevention of venous thromboembolism among patients with cancer. Thromb Res 133(Suppl 2):S122\u2013S127. https:\/\/doi.org\/10.1016\/S0049-3848(14)50021-7","journal-title":"Thromb Res"},{"issue":"5","key":"3365_CR74","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1177\/1076029617729215","volume":"24","author":"EP Dimakakos","year":"2018","unstructured":"Dimakakos EP, Vathiotis I, Syrigos K (2018) The role of tinzaparin in oncology. Clin Appl Thromb\/Hemost\u202f: Official J Int Acad Clin Appl Thromb\/Hemost 24(5):697\u2013707. https:\/\/doi.org\/10.1177\/1076029617729215","journal-title":"Clin Appl Thromb\/Hemost : Official J Int Acad Clin Appl Thromb\/Hemost"},{"issue":"3","key":"3365_CR75","doi-asserted-by":"publisher","first-page":"251","DOI":"10.23736\/S0026-4806.19.06026-9","volume":"110","author":"W Ageno","year":"2019","unstructured":"Ageno W, Barni S, Di Nisio M, Falanga A, Imberti D, Labianca RF et al (2019) Treatment of venous thromboembolism with tinzaparin in oncological patients. Minerva Med 110(3):251\u2013258. https:\/\/doi.org\/10.23736\/S0026-4806.19.06026-9","journal-title":"Minerva Med"},{"issue":"7","key":"3365_CR76","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1001\/jama.2015.9243","volume":"314","author":"AYY Lee","year":"2015","unstructured":"Lee AYY, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF et al (2015) Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA J Am Med Assoc 314(7):677\u2013686. https:\/\/doi.org\/10.1001\/jama.2015.9243","journal-title":"JAMA J Am Med Assoc"},{"issue":"2","key":"3365_CR77","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1177\/1076029617696581","volume":"24","author":"MJ Martinez-Zapata","year":"2018","unstructured":"Martinez-Zapata MJ, Mathioudakis AG, Mousa SA, Bauersachs R (2018) Tinzaparin for long-term treatment of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. Clin Appl Thromb\/Hemost\u202f: Official J Int Acad Clin Appl Thromb\/Hemost 24(2):226\u2013234. https:\/\/doi.org\/10.1177\/1076029617696581","journal-title":"Clin Appl Thromb\/Hemost : Official J Int Acad Clin Appl Thromb\/Hemost"},{"key":"3365_CR78","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.thromres.2017.07.004","volume":"157","author":"L Jara-Palomares","year":"2017","unstructured":"Jara-Palomares L, Solier-Lopez A, Elias-Hernandez T, Asensio-Cruz M, Blasco-Esquivias I, Marin-Barrera L et al (2017) Tinzaparin in cancer associated thrombosis beyond 6months: TiCAT study. Thromb Res 157:90\u201396. https:\/\/doi.org\/10.1016\/j.thromres.2017.07.004","journal-title":"Thromb Res"},{"issue":"6","key":"3365_CR79","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.ejvs.2004.02.029","volume":"29","author":"ME Daskalopoulos","year":"2005","unstructured":"Daskalopoulos ME, Daskalopoulou SS, Tzortzis E, Sfiridis P, Nikolaou A, Dimitroulis D et al (2005) Long-term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. Euro J Vas Endovas Surg\u202f: Official J Euro Soc Vas Surg 29(6):638\u2013650. https:\/\/doi.org\/10.1016\/j.ejvs.2004.02.029","journal-title":"Euro J Vas Endovas Surg : Official J Euro Soc Vas Surg"},{"issue":"5","key":"3365_CR80","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1177\/1076029613481845","volume":"19","author":"RD Hull","year":"2013","unstructured":"Hull RD, Liang J, Merali T (2013) Effect of long-term LMWH on post-thrombotic syndrome in patients with iliac\/noniliac venous thrombosis: a subanalysis from the home-LITE study. Clin Appl Thromb\/Hemost\u202f: Official J Int Acad Clin Appl Thromb\/Hemost 19(5):476\u2013481. https:\/\/doi.org\/10.1177\/1076029613481845","journal-title":"Clin Appl Thromb\/Hemost : Official J Int Acad Clin Appl Thromb\/Hemost"},{"issue":"4","key":"3365_CR81","first-page":"683","volume":"12","author":"SA Mousa","year":"2004","unstructured":"Mousa SA, Mohamed S (2004) Anti-angiogenic mechanisms and efficacy of the low molecular weight heparin, tinzaparin: anti-cancer efficacy. Oncol Rep 12(4):683\u2013688","journal-title":"Oncol Rep"},{"issue":"20","key":"3365_CR82","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1182\/blood-2014-08-595686","volume":"125","author":"AT Bauer","year":"2015","unstructured":"Bauer AT, Suckau J, Frank K, Desch A, Goertz L, Wagner AH et al (2015) von Willebrand factor fibers promote cancer-associated platelet aggregation in malignant melanoma of mice and humans. Blood 125(20):3153\u20133163. https:\/\/doi.org\/10.1182\/blood-2014-08-595686","journal-title":"Blood"},{"issue":"9","key":"3365_CR83","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1046\/j.1538-7836.2003.00341.x","volume":"1","author":"A Amirkhosravi","year":"2003","unstructured":"Amirkhosravi A, Mousa SA, Amaya M, Francis JL (2003) Antimetastatic effect of tinzaparin, a low-molecular-weight heparin. J Thromb Haemost 1(9):1972\u20131976. https:\/\/doi.org\/10.1046\/j.1538-7836.2003.00341.x","journal-title":"J Thromb Haemost"},{"issue":"2","key":"3365_CR84","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.bcp.2015.07.013","volume":"97","author":"DB Pfankuchen","year":"2015","unstructured":"Pfankuchen DB, Stolting DP, Schlesinger M, Royer HD, Bendas G (2015) Low molecular weight heparin tinzaparin antagonizes cisplatin resistance of ovarian cancer cells. Biochem Pharmacol 97(2):147\u2013157. https:\/\/doi.org\/10.1016\/j.bcp.2015.07.013","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"3365_CR85","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1158\/1078-0432.CCR-06-1987","volume":"13","author":"JR Harvey","year":"2007","unstructured":"Harvey JR, Mellor P, Eldaly H, Lennard TW, Kirby JA, Ali S (2007) Inhibition of CXCR4-mediated breast cancer metastasis: a potential role for heparinoids? Clin Cancer Research\u202f: Official J Am Assoc Cancer Res 13(5):1562\u20131570. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-1987","journal-title":"Clin Cancer Research : Official J Am Assoc Cancer Res"},{"issue":"19 Pt 1","key":"3365_CR86","doi-asserted-by":"publisher","first-page":"7003","DOI":"10.1158\/1078-0432.CCR-05-1131","volume":"11","author":"JL Stevenson","year":"2005","unstructured":"Stevenson JL, Choi SH, Varki A (2005) Differential metastasis inhibition by clinically relevant levels of heparins\u2013correlation with selectin inhibition, not antithrombotic activity. Clin Cancer Research\u202f: Official J Am Assoc Cancer Res 11(19 Pt 1):7003\u20137011. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-1131","journal-title":"Clin Cancer Research : Official J Am Assoc Cancer Res"},{"issue":"1","key":"3365_CR87","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1055\/s-2002-20559","volume":"28","author":"SA Mousa","year":"2002","unstructured":"Mousa SA (2002) Anticoagulants in thrombosis and cancer: the missing link. Semin Thromb Hemost 28(1):45\u201352. https:\/\/doi.org\/10.1055\/s-2002-20559","journal-title":"Semin Thromb Hemost"},{"key":"3365_CR88","doi-asserted-by":"publisher","unstructured":"Sarantis P, Bokas A, Papadimitropoulou A, Koustas E, Theocharis S, Papakotoulas P et al (2021) Combinatorial treatment of tinzaparin and chemotherapy can induce a significant antitumor effect in pancreatic cancer. Int J Mole Sci 22(13).\u00a0https:\/\/doi.org\/10.3390\/ijms22137053","DOI":"10.3390\/ijms22137053"},{"key":"3365_CR89","doi-asserted-by":"publisher","unstructured":"Karamouzis MV, Athanasiadis I, Samelis G, Vallilas C, Bokas A, Nikolaidi A et al (2021) The impact of thromboprophylaxis on the survival of patients with advanced pancreatic cancer. The Pancreatic Cancer and Tinzaparin (PaCT) Study. Cancers (Basel) 13(12). https:\/\/doi.org\/10.3390\/cancers13122884","DOI":"10.3390\/cancers13122884"},{"issue":"8","key":"3365_CR90","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1007\/s00134-020-06088-1","volume":"46","author":"BS Joly","year":"2020","unstructured":"Joly BS, Siguret V, Veyradier A (2020) Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19. Intensive Care Med 46(8):1603\u20131606. https:\/\/doi.org\/10.1007\/s00134-020-06088-1","journal-title":"Intensive Care Med"},{"issue":"3","key":"3365_CR91","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.chest.2020.05.559","volume":"158","author":"LK Moores","year":"2020","unstructured":"Moores LK, Tritschler T, Brosnahan S, Carrier M, Collen JF, Doerschug K et al (2020) Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST Guideline and Expert Panel Report. Chest 158(3):1143\u20131163. https:\/\/doi.org\/10.1016\/j.chest.2020.05.559","journal-title":"Chest"},{"issue":"12","key":"3365_CR92","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1055\/a-1475-2351","volume":"121","author":"M Goldin","year":"2021","unstructured":"Goldin M, Giannis D, Diab W, Wang J, Khanijo S, Sharifova G et al (2021) Treatment-dose LMWH versus prophylactic\/intermediate dose heparins in high-risk COVID-19 inpatients: rationale and design of the HEP-COVID Trial. Thromb Haemost 121(12):1684\u20131695. https:\/\/doi.org\/10.1055\/a-1475-2351","journal-title":"Thromb Haemost"},{"issue":"4","key":"3365_CR93","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1161\/CIRCRESAHA.120.317447","volume":"127","author":"JD McFadyen","year":"2020","unstructured":"McFadyen JD, Stevens H, Peter K (2020) The emerging threat of (micro)thrombosis in COVID-19 and its therapeutic implications. Circ Res 127(4):571\u2013587. https:\/\/doi.org\/10.1161\/CIRCRESAHA.120.317447","journal-title":"Circ Res"},{"key":"3365_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2020.109743","volume":"142","author":"FB Belen-Apak","year":"2020","unstructured":"Belen-Apak FB, Sarialioglu F (2020) The old but new: can unfractioned heparin and low molecular weight heparins inhibit proteolytic activation and cellular internalization of SARS-CoV2 by inhibition of host cell proteases? Med Hypotheses 142:109743. https:\/\/doi.org\/10.1016\/j.mehy.2020.109743","journal-title":"Med Hypotheses"},{"issue":"1","key":"3365_CR95","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1186\/s13054-020-03375-7","volume":"24","author":"S Jonmarker","year":"2020","unstructured":"Jonmarker S, Hollenberg J, Dahlberg M, Stackelberg O, Litorell J, Everhov AH et al (2020) Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients. Crit Care 24(1):653. https:\/\/doi.org\/10.1186\/s13054-020-03375-7","journal-title":"Crit Care"},{"key":"3365_CR96","doi-asserted-by":"publisher","unstructured":"Khurram R, Johnson FTF, Naran R, Hare S (2020) Spontaneous tension pneumothorax and acute pulmonary emboli in a patient with COVID-19 infection. BMJ Case Rep 13(8). https:\/\/doi.org\/10.1136\/bcr-2020-237475","DOI":"10.1136\/bcr-2020-237475"},{"key":"3365_CR97","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12959-020-00235-w","volume":"18","author":"M Beckman","year":"2020","unstructured":"Beckman M, Nyren S, Kistner A (2020) A case-report of widespread pulmonary embolism in a middle-aged male seven weeks after asymptomatic suspected COVID 19 infection. Thromb J 18:19. https:\/\/doi.org\/10.1186\/s12959-020-00235-w","journal-title":"Thromb J"},{"key":"3365_CR98","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.thromres.2020.04.046","volume":"191","author":"R Bruggemann","year":"2020","unstructured":"Bruggemann R, Gietema H, Jallah B, Ten Cate H, Stehouwer C, Spaetgens B (2020) Arterial and venous thromboembolic disease in a patient with COVID-19: a case report. Thromb Res 191:153\u2013155. https:\/\/doi.org\/10.1016\/j.thromres.2020.04.046","journal-title":"Thromb Res"},{"key":"3365_CR99","doi-asserted-by":"publisher","unstructured":"Akinosoglou K, Savopoulos C, Pouliakis A, Triantafyllidis C, Markatis E, Golemi F et al (2022) Intensive-dose tinzaparin in hospitalized COVID-19 patients: the INTERACT study. Viruses 14(4). https:\/\/doi.org\/10.3390\/v14040767","DOI":"10.3390\/v14040767"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-022-03365-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-022-03365-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-022-03365-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T16:20:43Z","timestamp":1663431643000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-022-03365-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,23]]},"references-count":99,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["3365"],"URL":"https:\/\/doi.org\/10.1007\/s00228-022-03365-4","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,23]]},"assertion":[{"value":"3 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study does not require ethics approval.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}